949. Deputy Mark Ward asked the Minister for Health the reason the State is not pursuing fair pricing on an EU-wide basis regarding the topic of givinostat therapy for Duchenne muscular dystrophy; the reason this is only being considered in the context of the Irish market; if precedence for EU-wide negotiation has been used for drug pricing; and if she will make a statement on the matter. [45404/26]

Summary

949. Deputy Mark Ward asked the Minister for Health the reason the State is not pursuing fair pricing on an EU-wide basis regarding the topic of givinostat therapy for Duchenne muscular dystrophy; the reason this is only being considered in the context of the Irish market; if precedence for EU-wide negotiation has been used for drug pricing; and if she will make a statement on the matter. [45404/26]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products

  xml · EN · 16 June 2026

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.